Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

PURPOSE: Targeting CD79B using antibody–drug conjugates (ADC) is an effective therapeutic strategy in B-cell non-Hodgkin lymphoma (B-NHL). We investigated DCDS0780A, an anti-CD79B ADC with THIOMAB technology (TDC) that consistently conjugates two anti-neoplastic molecules per antibody, in contrast w...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera, Alex F., Patel, Manish R., Burke, John M., Advani, Ranjana, Cheson, Bruce D., Sharman, Jeff P., Penuel, Elicia, Polson, Andrew G., Liao, Chen Di, Li, Chunze, Schuth, Eva, Vaze, Anjali, Samineni, Divya, Elstrom, Rebecca, Cooper, James, Diefenbach, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365381/
https://www.ncbi.nlm.nih.gov/pubmed/34980599
http://dx.doi.org/10.1158/1078-0432.CCR-21-3261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365381/
https://www.ncbi.nlm.nih.gov/pubmed/34980599
http://dx.doi.org/10.1158/1078-0432.CCR-21-3261

Ejemplares similares